Johannes Textor

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

The Reticular Cell Network: A Robust Backbone for Immune Responses.

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.

Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report.

Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.

Is T Cell Negative Selection a Learning Algorithm?

Testing Graphical Causal Models Using the R Package "dagitty".

Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.

Local actin dynamics couple speed and persistence in a cellular Potts model of cell migration.

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity.

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome.

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.

Interpreting T-cell search "strategies" in the light of evolution under constraints.

In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome.